, Tracking Stock Market Picks
Enter Symbol:
Akebia Therapeutics Inc. (AKBA) [hlAlert]

down 69.39 %

Akebia Therapeutics Inc. (AKBA) rated Buy with price target $28 by UBS

Posted on: Monday,  Apr 14, 2014  12:00 AM ET by UBS

UBS rated Buy Akebia Therapeutics Inc. (NASDAQ: AKBA) on 04/14/2014, when the stock price was $21.14. Since
then, Akebia Therapeutics Inc. has lost 69.39% as of 12/15/2015's recent price of $6.47.
If you would have followed this UBS's recommendation on AKBA, you would have lost 69.39% of your investment in 610 days.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/14/2014 12:00 AM Buy
21.14 28.00
as of 10/17/2014
1 Week down  -1.53 %
1 Month down  -9.05 %
3 Months down  -12.77 %
1 YTD down  -3.07 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy